

PLOS Neglected Tropical Diseases

Factors Associated with In-Hospital Mortality of Adult Tetanus Patients– A Multicenter Study from Bangladesh --Manuscript Draft--

Manuscript Number:	PNTD-D-21-01768
Full Title:	Factors Associated with In-Hospital Mortality of Adult Tetanus Patients– A Multicenter Study from Bangladesh
Short Title:	Factors Associated with Mortality of Adult Tetanus Patients
Article Type:	Research Article
Keywords:	Tetanus; In-hospital mortality; Fatality; Risk factors
Abstract:	<p>Background: Tetanus, a vaccine-preventable disease, is still occurring in the elderly population of low- and middle-income countries with a high case-fatality rate. The objective of the study was to elucidate the factors associated with in-hospital mortality of tetanus in Bangladesh.</p> <p>Methods: This prospective observational study, conducted in two specialized infectious disease hospitals, conveniently selected adult tetanus patients (≥18 years) for inclusion. Data were collected through a preformed structured questionnaire. Kaplan Meier survival analysis and univariate and multivariable Cox regression analysis were carried out to assess factors associated with in-hospital mortality among patients. All analysis was done using Stata (version 16) and SPSS (version 26).</p> <p>Results: A total of 61 confirmed tetanus cases were included, and the overall in-hospital mortality rate was 34.4% (n=21). Patients had an average age of 46.49 ±15.65 years (SD), and the majority were male (96.7%), farmers (57.4%), and came from rural areas (93.4%). Survival analysis revealed that the probability of death was significantly higher among patients having an age of < 40 years, incubation time of ≤12 days, onset time of ≤ 4 days, and having complication(s). However, on multivariable Cox regression analysis, age (adjusted hazard ratio [aHR] 4.03, 95% Confidence Interval [CI] 1.07 – 15.17, p=0.039) and onset time (≤4 days) (aHR 3.33; 95% CI 1.05 – 10.57, p=0.041) came as significant predictors of in-hospital mortality after adjusting for incubation period and complications.</p> <p>Conclusion: Older age and short onset time are the two most important determinants of in-hospital mortality of tetanus patients. Hence, these patients require enhanced emphasis and care.</p>
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS NTDs for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p>	<p>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>

Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement **will appear in the published article** if the submission is accepted. Please make sure it is accurate. View published research articles from [PLOS NTDs](#) for specific examples.

The authors have declared that no competing interests exist.

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

Data Availability

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

Yes - all data are fully available without restriction

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because

All relevant data are within the manuscript and its Supporting Information files.

of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party and contact information or URL).

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

* typeset

Additional data availability information:

1 **Title: Factors Associated with In-Hospital Mortality of Adult Tetanus Patients–**
2 **A Multicenter Study from Bangladesh**

3 **Short title: Factors Associated with Mortality of Adult Tetanus Patients**

4 **Author' name:**

5 **Md. Abdullah Saeed Khan¹, Mohammad Jahid Hasan², Md Utba Rashid³, Soumik Kha**
6 **Sagar³, Sanzida Khan¹, Susmita Zaman², Sultan Mahamud Sumon¹, Ariful Basher¹,**
7 **Mohammad Delwer Hossain Hawlader⁴, Mohammad Hayatun Nabi⁴, Nadira Sultana**
8 **Kakoly⁴**

9

10 **Authors' Affiliations**

11

- 12 1. Infectious Disease Hospital, Mohakhali, Dhaka-1212, Bangladesh.
- 13 2. Pi Research Consultancy Center, Dhaka 1211, Bangladesh.
- 14 3. Nutrition and Clinical Services Division (NCSD), International Centre for
- 15 Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka-1212,
- 16 Bangladesh.
- 17 4. Department of Public Health, North South University, Dhaka 1229, Bangladesh.

18

19

20

21

22 **Corresponding Author:**

23 **Md. Abdullah Saeed Khan**

24 MBBS, MPH

25 Medical Officer

26 Infectious Disease Hospital,

27 Mohakhali, Dhaka – 1212, Bangladesh

28 Phone: +8801823210718

29 abdullahdmc@gmail.com; abdullah.saeed@northsouth.edu

30 <https://orcid.org/0000-0002-0707-0437>

31 Mobile no: +8801823210718

32

33

ABSTRACT

34 **Background:** Tetanus, a vaccine-preventable disease, is still occurring in the elderly
35 population of low- and middle-income countries with a high case-fatality rate. The
36 objective of the study was to elucidate the factors associated with in-hospital mortality
37 of tetanus in Bangladesh.

38 **Methods:** This prospective observational study, conducted in two specialized
39 infectious disease hospitals, conveniently selected adult tetanus patients (≥ 18 years) for
40 inclusion. Data were collected through a preformed structured questionnaire. Kaplan
41 Meier survival analysis and univariate and multivariable Cox regression analysis were
42 carried out to assess factors associated with in-hospital mortality among patients. All
43 analysis was done using Stata (version 16) and SPSS (version 26).

44 **Results:** A total of 61 confirmed tetanus cases were included, and the overall in-
45 hospital mortality rate was 34.4% (n=21). Patients had an average age of 46.49 ± 15.65
46 years (SD), and the majority were male (96.7%), farmers (57.4%), and came from rural
47 areas (93.4%). Survival analysis revealed that the probability of death was significantly
48 higher among patients having an age of < 40 years, incubation time of ≤ 12 days, onset
49 time of ≤ 4 days, and having complication(s). However, on multivariable Cox
50 regression analysis, age (adjusted hazard ratio [aHR] 4.03, 95% Confidence Interval
51 [CI] 1.07 – 15.17, $p=0.039$) and onset time (≤ 4 days) (aHR 3.33; 95% CI 1.05 – 10.57,
52 $p=0.041$) came as significant predictors of in-hospital mortality after adjusting for
53 incubation period and complications.

54 **Conclusion:** Older age and short onset time are the two most important determinants
55 of in-hospital mortality of tetanus patients. Hence, these patients require enhanced
56 emphasis and care.

57

58 **Keywords:** *Tetanus; In-hospital mortality; Fatality; Risk factors.*

59

60 **Synopsis**

61 The incidence of tetanus decreased considerably from the developed countries through mass
62 vaccination programs. However, it continues to be a cause of death in low- and middle-income
63 settings. Tetanus mortality after hospitalization is dependent on many factors. Our study found
64 that more than one-third of the adult (≥ 18 years) tetanus patients died in the hospitals without
65 intensive care facilities, and patients' older age, short incubation period (time from injury to the
66 appearance of symptom), short onset time (interval between the first symptoms and the first
67 spasm) and development of complications were significantly associated with deaths.
68 Meticulous and individualized management of adult tetanus patients with one or more of the
69 above features are required to increase their survival.

70

71

72 **Introduction**

73 Tetanus, an acute and fatal infection, is caused by the neurotoxin-producing bacterium
74 *Clostridium tetani*. It shows a classical clinical picture of muscular rigidity and
75 generalized spasms (1). The spores of *C. tetani* are resilient, long-lasting, and
76 widespread in the environment. It can contaminate wounds, abrasions, and the
77 umbilical stump in neonates(2). Globally nearly one million people contract tetanus
78 annually. It has a high case fatality rate, with an estimated 45.5% (95% CI: 43.7%-
79 47.2%) deaths in African countries(3). However, it might vary based on the availability
80 and accessibility of intensive care units that are well-equipped. Extensive vaccination
81 coverage has led to a decline in the number of new cases of tetanus in developed
82 countries. However, it is still common in low- and middle-income countries. South Asia
83 and Sub-Saharan Africa account for 82% of tetanus cases worldwide(4). In Bangladesh
84 the prevalence is still unknown(5).

85 Any unvaccinated person has the potential risk of developing tetanus because of the
86 absence of immune protection from natural infection. As childhood and maternal
87 vaccination was started at the end of the twentieth century, tetanus now occurs mainly
88 among older adults in developed countries. On the other hand, neonatal tetanus, which
89 occurs primarily due to inadequate or lack of women's immunization, is frequently
90 found in developing or underdeveloped settings (6). Despite the availability of
91 inexpensive and effective tetanus vaccines, the disease continues to be a health problem
92 in impoverished regions of the world (7).

93 *C tetani* spores invade the human body through wounds or minor abrasions under
94 suitable anaerobic conditions. Whenever a wound occurs, appropriate wound care and
95 vaccination could prevent tetanus(8). If infection occurs, patients often die in the
96 hospital due to autonomic failure, cardiovascular dysrhythmia, and complications (9).
97 Proper management can improve survival among patients(10). However, despite
98 appropriate management, many patients fail to survive.

99 Death in tetanus is dependent on many factors. The poor prognostic factors of in-
100 hospital deaths identified are short incubation period, older age, severe type,
101 generalized variety, dysautonomia, pneumonia, hypoxemia, sepsis, and renal
102 failure(11). Hence, the treatment of cases often requires assisted ventilation.
103 Additionally, passive immunization is usually given following trauma or injury (12).
104 Despite widespread vaccination and advances in management, the mortality in
105 generalized tetanus is still high. Previously, very few studies prospectively explored the
106 factors associated with in-hospital mortality among adult tetanus patients. Moreover,
107 there are few to no studies regarding in-hospital mortality and its associated factors
108 among adult tetanus patients in Bangladesh. Therefore, this research aimed to analyze
109 the factors affecting mortality in hospitalized adult tetanus patients.

110

111 **Materials and Methods**

112 **Study design, population, and settings**

113 This prospective observation was carried out in two specialized infectious disease
114 hospitals in Bangladesh (Infectious Disease Hospital, Mohakhali, Dhaka, and Surya
115 Kanto Hospital, Mymensingh), between December 2020 to August 2021. We
116 approached all adult (≥ 18 years) hospitalized cases of tetanus inclusion. Patients who
117 were not willing to participate were excluded. A total of 61 clinically diagnosed tetanus
118 patients were conveniently selected for the study.

119 **Study measures**

120 After an extensive review of the published literature, we produced a structured
121 questionnaire for data collection (Supplementary file 1). The questionnaire had four
122 parts: a.) sociodemographic information, b.) information regarding tetanus, c.)
123 comorbidities, investigations, and treatment, d.) in-hospital outcome.

124 *Sociodemographic information*

125 This part queried the patient's age, sex, religion, education, marital status, occupation,
126 monthly family income, and smoking history.

127 *Information regarding tetanus*

128 This part asked about the mode of injury, place of wound, onset time (duration between
129 onset of symptoms and full-blown expression), incubation period, clinical features
130 (including symptoms and signs) at admission, vaccination history (both previous and

131 postexposure), tetanus types, and investigations. The clinical characteristics comprised
132 of- incubation period (time from injury to the appearance of symptom), time of onset
133 or onset time (interval between the first symptoms and the first spasm), trismus
134 (lockjaw), risus sardonicus (a characteristic, abnormal, sustained spasm of the facial
135 muscles), dysphagia, muscle spasms (other skeletal muscles), spasticity, rigidity
136 (overall), abdominal rigidity, opisthotonus (spasm of the muscles causing backward
137 arching of the head, neck, and spine), fever, palpitation, urinary retention and vital
138 signs.

139 *Comorbidities, investigations, and treatment*

140 Patients' comorbidities, including diabetes mellitus, hypertension, chronic obstructive
141 pulmonary disease, chronic renal failure, stroke, and ischemic heart disease, were
142 assessed in this section. Additionally, the information about routine investigations
143 (hematological profile, serum creatinine, serum calcium, and electrolytes) and
144 treatment received during the hospital stay was also collected.

145 *In-hospital outcome*

146 Complications and final outcomes of the patients were listed in this section.

147 **Study procedure**

148 At first, informed written consent was taken from the patients or attendants of
149 unconscious patients at admission for inclusion into this study. Then we recorded
150 patients' socio-economic data, vaccination history, clinical characteristics, and
151 comorbidity data upon inclusion. Patients presenting with lockjaw (trismus) or risus

152 sardonicus and one or more features from dysphagia, muscle spasms, abdominal
153 rigidity, opisthotonos, and history of the wound were considered to have clinically
154 confirmed tetanus. The presence of an infected wound was considered an essential
155 diagnostic clue in the absence of trismus or risus sardonicus. After the initial
156 assessment, patients were followed up during the hospital stay until discharge with
157 recovery or death. Finally, investigation reports and in-hospital outcome data,
158 including complications were recorded in the questionnaire.

159

160 **Statistical Analysis**

161 After data entry and curation, we performed descriptive and analytic statistics.
162 Descriptive statistic was expressed as frequency (proportion) for categorical variable
163 and mean \pm standard deviation or median (interquartile range) for continuous variable.
164 Univariate analyses were conducted using the chi-square test, independent samples t
165 test, Mann-Whitney U test, and Kaplan Meyer Survival analysis. Univariate and
166 multivariable Cox regression analyses were used for the assessment of significant
167 factors associated with death. Only statistically significant factors ($p < 0.05$) at univariate
168 analysis, including age, incubation period, onset time, and presence of complication,
169 were considered for Cox regression. A p-value of ≤ 0.05 was considered significant.
170 Statistical analysis was performed using statistical software Stata (version 16).

171


172 **Ethical Consideration**

173 The study was approved by the Ethical Review Committee of North South University
174 (2020/OR-NSU/IRB-No.0801). All procedures were conducted following guidelines
175 laid out by the World Medical Association Declaration of Helsinki. Informed written
176 consent was obtained from patients or attendants of unconscious patients before their
177 inclusion in the study.


178

179

180 **Result**

181  prevalence of in-hospital mortality was 34.4% (21 out of 61) in this study. (**Figure**
182 **1**).

183 **Figure 1. In-hospital mortality of tetanus patients**

184 The average age of all patients was 46.49 ± 15.65 years. The mean age of patients who
185 died (52.10 ± 12.99 years) was significantly higher than that of recovered patients
186 (43.55 ± 16.26 years, $p=0.042$). Among patients who died, 80.9% were aged ≥ 40 years,
187 and among those who were alive, 55.0% had the same age ($p=0.045$). The majority
188 patients were male (96.7%), illiterate (46.7%), married (76.7%), farmer (57.4%), had
189 income < 7500  T (42.6%), and came from rural area (93.4%). The distribution was
190 statistically similar among patients who were alive and who died (**Table 1**).

191 **Table 1. Sociodemographic characteristics of the patients (n=61)**

Variable	Total n (%)	Recovered n (%)	Died n (%)	p-value
Age (years), mean \pm SD	46.49 \pm 15.65	43.55 \pm 16.26	52.10 \pm 12.99	0.042
Age category (years)				
< 40	22 (36.1)	18 (45.0)	4 (19.1)	0.045
≥ 40	39 (63.9)	22 (55.0)	17 (80.9)	
Sex				

Male	59 (96.7)	38 (95.0)	21 (100.0)	0.297
Female	2 (3.28)	2 (5.0)	0	
Education				
Illiterate	28 (46.7)	18 (45.0)	10 (50.0)	0.986
Primary	11 (27.5)	5 (25.0)	16 (26.7)	
SSC	13 (21.7)	9 (22.5)	4 (20.0)	
HSC and above	3 (5.0)	2 (5.0)	1 (5.0)	
Marital Status				
Unmarried	9 (15.0)	6 (15.4)	3 (14.3)	0.967
Married	46 (76.7)	30 (76.9)	16 (76.2)	
Widowed/divorced	5 (8.3)	3 (7.7)	2 (9.5)	
Occupation				
Farmer	35 (57.4)	20 (50.0)	15 (71.4)	0.273
Businessman	6 (9.8)	6 (15.0)	0	
Service holder	5 (8.2)	3 (7.5)	2 (9.5)	
Carpenter	4 (6.7)	1 (2.5)	3 (14.3)	
Housewife	2 (3.3)	2 (5.0)	0	
Student	2 (3.3)	1 (2.5)	1 (4.8)	
Electrician	2 (3.3)	2 (5.0)	0	
Retired	2 (3.3)	2 (5.0)	0	
Tailor	1 (1.6)	1 (2.5)	0	
Driver	1 (1.6)	1 (2.5)	0	
Fisherman	1 (2.0)	1 (1.6)	0	
Income (BDT)				

<7500	26 (42.6)	18 (45.0)	8 (38.1)	0.382
7501 – 10000	13 (21.3)	9 (22.5)	4 (19.1)	
10001 – 15000	16 (26.2)	11 (27.5)	5 (23.8)	
>15000	6 (9.8)	2 (5.0)	4 (19.0)	
Residence				
Rural	57 (93.4)	39 (97.5)	18 (85.7)	0.077
Urban	4 (6.56)	1 (2.5)	3 (14.3)	

192 p-value determined using independent samples t test and Chi-square test where

193 appropriate; Significant p-values were shown in bold face



194

195 Of all, 8.2% had at least one comorbidity, 6.7% had hypertension, 4.9% had diabetes
 196 mellitus, 1.6% had COPD, and 1.6% had ischemic heart disease. Thirty-six percent of
 197 patients were current smokers, 20% were past smokers, and 44% never smoked (Table
 198 2).

199 **Table 2. Comorbidity and smoking habit of the patients (n=61)**

Variable	Total n (%)	Recovered n (%)	Died n (%)	p-value
Comorbidity				
Present (any)	5 (8.2)	2 (5.0)	3 (14.3)	0.209
Absent	56 (91.8)	38 (95.0)	18 (85.7)	
Diabetes Mellitus				
Present	3 (4.9)	1 (2.5)	2 (9.5)	0.228
Absent	58 (95.1)	39 (97.5)	19 (90.5)	
Hypertension				
Present	4 (6.7)	1 (2.5)	3 (14.3)	0.077
Absent	57 (93.4)	39 (97.5)	18 (85.7)	
Chronic Obstructive Pulmonary Disease				
Present	1 (1.6)	0	1 (4.8))	0.164
Absent	60 (98.4)	40 (100.0)	20 (95.2)	
Ischemic heart disease				
Yes	1 (1.6)	0	1 (4.8)	0.164
No	60 (98.4)	40 (100.0)	20 (95.2)	
Smoking habit*				
Current smoker	9 (36.0)	7 (36.8)	2 (33.3)	0.940
Past smoker	5 (20.0)	4 (21.1)	1 (16.7)	
Never smoker	11 (44.0)	8 (42.1)	3 (50.0)	

200 *After excluding missing cases

201 p-value determined by Chi-square test

202

203 **Table 3** presents the clinical characteristics of the patients. Only 6.6% of patients
204 asserted a history of vaccination against tetanus, and 24.6% of patients took
205 postexposure prophylaxis. The main mode of injury was trauma (95.1%), and the
206 majority had their wound in the extremities (91.8%). Most of the patients had the
207 generalized type of tetanus (93.4%) and severe disease (45.9%). These features were
208 statistically similar between alive and dead patients. The overall median onset time was
209 3 days (interquartile range [IQR]: 2 – 7). It was statistically similar among patients who
210 died (2.5, IQR 2- 4) than those who were alive (4, IQR 2 – 10, p=0.076). The median
211 incubation period was 14 days (IQR 8 – 15) overall. It was also statistically similar
212 between deceased patients (12, IQR 7 – 15) and alive patients (15, IQR 10 – 16, p
213 =0.058). However, when categorized at a cutoff point of 12 days, a statistically
214 significantly higher proportion of dead patients had an incubation period of ≤ 12 days
215 compared to those alive (p=0.043). Of all patients, the majority had severe trismus
216 (33.9%), mild dysphagia (50%), short spasms (73.5%), and generalized rigidity
217 (93.4%). Spasticity was present in 75.4% of patients, abdominal rigidity in 68.9%, fever
218 in 41%, opisthotonus in 9.8%, and urinary retention in 9.8%. Vital signs were within
219 the normal range. The distribution of the clinical features were statistically similar
220 between patients who was alive and those who died.

221

222 **Table 3. Clinical characteristics of the patients (n=61)**

223

Variable	Total n (%)	Recovered n (%)	Died n (%)	p-value
Prior history of vaccination against tetanus				
Present	4 (6.6)	3 (7.5)	1 (4.8)	0.566
Absent	19 (31.2)	14 (35.0)	5 (23.8)	
Don't know	38 (62.3)	23 (57.5)	15 (71.4)	
Postexposure prophylaxis				
Taken	15 (24.6)	10 (25.0)	5 (23.8)	0.602
Not taken	40 (65.6)	25 (62.5)	15 (71.4)	
Don't know	6 (9.8)	5 (12.5)	1 (4.8)	
Mode of injury				
Post-traumatic	58 (95.1)	37 (92.5)	21 (100.0)	0.209
Postsurgery	3 (4.9)	3 (7.5)	0	
Place of wound				
Extremities	56 (91.8)	36 (90.0)	20 (95.2)	0.479
Head/face	5 (8.2)	4 (10.0)	1 (4.8)	
Tetanus type				
Generalized	57 (93.4)	37 (92.5)	20 (95.2)	0.681
Localized	4 (6.7)	3 (7.5)	1 (4.8)	

Time of onset (days), median (IQR)*	3 (2 – 7)	4 (2 – 10)	2.5 (2 – 4)	0.076
> 4 days	20 (36.4)	16 (45.7)	4 (20.0)	0.057
≤ 4 days	35 (63.6)	19 (54.3)	16 (80.0)	
Incubation period (days), median (IQR)*	14 (8 – 15)	15 (10 – 16)	12 (7 – 15)	0.058
> 12 days	28 (52.8)	21 (63.6)	7 (35.0)	0.043
≤ 12 days	25 (47.2)	12 (36.4)	13 (65.0)	
Tetanus severity				
Mild	11 (18.0)	8 (20.0)	3 (14.3)	0.871
Moderate	18 (29.5)	12 (30.0)	6 (28.6)	
Severe	28 (45.9)	18 (45.0)	10 (47.6)	
Very severe	4 (6.6)	2 (5.0)	2 (9.5)	
Trismus*				
Absent	1 (1.7)	1 (2.6)	0	0.677
Mild	8 (13.6)	6 (15.4)	2 (10.0)	
Moderate	30 (50.8)	21 (53.8)	9 (45.0)	
Severe	20 (33.9)	11 (28.2)	9 (45.0)	
Risus sardonicus				
Present	5 (8.2)	4 (10.0)	1 (4.8)	0.479
Absent	56 (91.8)	36 (90.0)	20 (95.2)	
Dysphagia*				

Absent	6 (10.7)	3 (8.6)	3 (14.3)	0.378
Mild	28 (50.0)	20 (57.1)	8 (38.1)	
Severe	22 (39.3)	12 (34.3)	10 (47.6)	
Spasms*				
Short	25 (73.5)	15 (71.4)	10 (76.9)	0.724
Prolonged	9 (26.5)	6 (28.6)	3 (23.1)	
Spasticity				
Present	46 (75.4)	31 (77.5)	15 (71.4)	0.601
Absent	15 (24.6)	9 (22.5)	6 (28.6)	
Rigidity				
Localized	4 (6.6)	3 (7.5)	1 (4.8)	0.681
Generalized	57 (93.4)	37 (92.5)	20 (95.2)	
Abdominal rigidity				
Present	42 (68.9)	26 (65.0)	16 (76.2)	0.370
Absent	19 (31.2)	14 (35.0)	5 (23.8)	
Opisthotonus				
Present	6 (9.8)	6 (15.0)	0	0.062
Absent	55 (90.2)	34 (85.0)	21 (100.0)	
Fever				
Present	25 (41.0)	15 (37.5)	10 (47.6)	0.445
Absent	36 (59.0)	25 (62.5)	11 (52.4)	
Palpitation				

Present	6 (9.8)	4 (10.0)	2 (9.5)	0.953
Absent	55 (90.2)	36 (90.0)	19 (90.5)	
Urinary retention				
Present	6 (9.8)	6 (15.0)	0	0.069
Absent	55 (90.2)	34 (85.0)	21 (100.0)	
Pulse (b/min), mean±SD	82.9 ±1.6	80.0 ±1.9	88.2 ±2.3	0.011
Systolic blood pressure (mmHg), mean±SD	111.4 ±1.9	109.0 ±2.1	115.8 ±3.6	0.087
Diastolic blood pressure (mmHg), mean±SD	73.0 ±1.4	73.9 ±1.9	71.5 ±1.9	0.433
Temperature (F), mean±SD	97.8 ±0.6	97.2 ±0.9	98.7 ±0.3	0.214
Respiratory rate (breaths/min)	20 ±0.6	19.5 ±0.8	20.9 ±0.9	0.256

224 *Excluding missing values

225 p-value determined by Mann-Whitney U test, independent samples t test and Chi-

226 square test where appropriate; Significant p-values are shown in boldface.

227

228

229 Hematological profile, random blood sugar, serum creatinine, calcium, and electrolytes

230 were statistically similar between alive and dead patients except for serum sodium

231 which was significantly higher in patients who died (141.9±1.8 mmol/l) than that of
 232 those who were alive (138.0±0.9 mmol/l, p=0.034). However, the average sodium level
 233 was within the normal range for both groups of patients (**Table 4**).

234 **Table 4. Investigation profile of participants**

Variable	Total Mean ±SD	Recovered Mean ±SD	Died Mean ±SD	p-value
Hemoglobin (g/dl)	12.2 ±0.2	12.2 ±0.3	12.1 ±0.5	0.800
RBC (10⁹/mm³)	4.44 ±0.2	4.3 ±0.2	4.7 ±0.2	0.394
WBC (10³/mm³)	9.9 ±0.5	9.4 ±0.6	10.9 ±0.6	0.154
Neutrophil (%)	73.1 ±1.4	71.6 ±1.6	76.9 ±2.5	0.091
Lymphocyte (%)	20.8 ±1.3	22.4 ±1.6	17.1 ±2.2	0.065
Platelet (10⁶/mm³)	237.6 ±12.8	240.9 ±16.5	229.5 ±19.1	0.694
ESR (mm)	22.8 ±1.7	22.7 ±2.2	23.4 ±2.6	0.853
RBS (mmol/l)	7.1 ±0.5	7.3 ±0.7	6.8 ±0.3	0.604
Serum calcium (mg/dl)	7.9 ±0.03	7.9 ±0.05	7.9 ±0.03	0.765
Serum creatinine (mg/dl)	1.2 ±0.1	1.2 ±0.1	1.2 ±0.1	0.948
Serum electrolyte (mmol/l)				
Sodium	139.3 ±0.9	138.0 ±0.9	141.9 ±1.8	0.034
Potassium	4.4 ±0.7	3.7 ±0.1	5.6 ±1.8	0.178
Chloride	107.5 ±1.02	106.2 ±1.1	109.8 ±1.9	0.095

235

236 RBC: Red blood cell; WBC: White blood cell

237 p-value determined by independent samples t test; Significant p-values were shown in

238 bold font

239

240 Out of 61 patients, 26 (42.6%) developed at least one complication, and this proportion

241 was significantly higher in dead patients (61.9%) compared to that of alive patients

242 (32.5%, $p=0.027$). The most common complication was hypoxemia (31.1%) followed

243 by aspiration pneumonia (19.6%), bedsore (13.1%), dysautonomia (6.5%), DVT

244 (4.9%), UTI (3.28%), sepsis (1.6%), thrombophlebitis (1.6%), and wound infection

245 (1.6%). The individual distribution of the complications was statistically similar

246 between the alive and dead patient groups (**Table 5**).

247 **Table 5. List of complications among patients (n=61)**

Variable	Total n (%)	Recovered n (%)	Died n (%)	p-value
Any complication				
Present	26 (42.6)	13 (32.5)	13 (61.9)	0.027
Absent	35 (57.4)	27 (67.5)	8 (38.1)	
Hypoxemia				
Present	19 (31.1)	6 (15.0)	13 (61.9)	0.164
Absent	42 (68.9)	34 (85.0)	8 (38.1)	

Aspiration Pneumonia				
Present	12 (19.6)	5 (12.5)	7 (33.3)	0.05
Absent	57 (93.4)	39 (97.5)	18 (85.7)	
Bedsore				
Present	8 (13.1)	7 (17.5)	1 (4.8)	0.161
Absent	53 (86.9)	33 (82.5)	20 (95.2)	
Dysautonomia				
Present	4 (6.5)	2 (5.0)	2 (9.5)	0.498
Absent	57 (93.4)	38 (95.0)	19 (90.5)	
DVT				
Present	3 (4.9)	1 (2.5)	2 (9.5)	0.228
Absent	58 (95.1)	39 (97.5)	19 (90.5)	
UTI				
Present	2 (3.2)	2 (5.0)	0	0.297
Absent	59 (96.7)	38 (95.0)	21 (100.0)	
Sepsis				
Present	1 (1.6)	1 (2.5)	0	0.465
Absent	60 (98.4)	39 (97.5)	21 (100.0)	
Thrombophlebitis				
Present	1 (1.6)	0	1 (4.8)	0.164
Absent	60 (98.4)	40 (100.0)	20 (95.2)	
Wound infection				

Present	1 (1.6)	1 (2.5)	0	0.465
Absent	60 (98.4)	39 (97.5)	21 (100.0)	

248 p-value determined by Chi-square test; Significant p-values are shown in bold face;

249 DVT: Deep Vein Thrombosis; UTI: Urinary Tract Infection.

250

251 The median duration of hospital stay of the patients was 11 days (IQR: 6 – 21 days)
 252 (**Figure 2**). Recovered patients had a significantly longer duration of stay (median 17
 253 days; IQR: 10 – 23 days) than those who died (median 5 days; IQR: 2 – 8 days)
 254 ($p < 0.001$).

255

256 **Figure 2. Boxplots showing the duration of hospital stay among tetanus patients**
 257 **categorized by outcome**

258

259 Kaplan-Meier survival analysis showed that the probability of survival among tetanus
 260 patients at 40 days after admission was 0.6, and it was statistically significantly better
 261 among patients with an age of < 40 years, incubation time of ≤ 12 days, onset time of
 262 ≤ 4 days and no complications (**Figure 3**).

263

264 **Figure 3. Kaplan-Meier survival curves showing the probability of overall**
 265 **survival and survival across different groups of tetanus patients**

266

267 Only factors that were significant ($p < 0.05$) in Kaplan-Meier survival analysis were
268 considered for univariate and multivariable Cox regression models to determine their
269 associations with the in-hospital mortality of tetanus patients (Table 6). After adjusting
270 for incubation period and complications, only age (≥ 40 years) and onset time (≤ 4 days)
271 were found to be significant predictors of tetanus case-fatality in the hospital. Tetanus
272 patients aged ≥ 40 years were 4.03 times (95% CI 1.07 – 15.17, $p = 0.039$) more likely to
273 die due to tetanus than those aged < 40 years. Patients with an onset time of ≤ 4 days were
274 significantly more likely (aHR 3.33; 95% CI 1.05 – 10.57, $p = 0.041$) to die in the hospital
275 than those with a higher onset time.

276 **Table 6. Univariate and multivariable Cox regression analysis for factors**
277 **associated with in-hospital mortality among tetanus patients**

Factors	Reference Category	Crude HR (95%CI)	p-value	Adjusted HR (95%CI)	p-value
Age group (≥ 40 years)	< 40 years	2.98 (0.99 – 9.02)	0.053	4.03 (1.07 – 15.17)	0.039
Incubation period (≤ 12 days)	> 12 days	2.57 (0.96 – 6.85)	0.059	2.49 (0.90 – 6.90)	0.078
Onset time (≤ 4 days)	> 4 days	2.94 (0.97 – 8.97)	0.058	3.33 (1.05 – 10.57)	0.041

Complication (Present)	Absent	2.79 (1.06 – 7.34)	0.038	2.09 (0.72 – 6.07)	0.175
---------------------------	--------	--------------------	--------------	--------------------	-------

278 HR: Hazard ratio; Significant p-values are shown in boldface.

279

280 Discussion

281 Tetanus is a vaccine-preventable disease that is still continuing to infect people,
 282 particularly, in low-income and middle-income countries. As the spore of the causative
 283 organism *C. tetani* remains widespread in the environment, its eradication is
 284 impossible. On the other hand, life-long immunity against tetanus requires three booster
 285 doses of vaccine during the adolescent years (13). Currently, only women of
 286 childbearing age are targeted through booster vaccination programs, which have
 287 substantially reduced maternal and neonatal tetanus in many countries. However, it
 288 remains a problem for adults in South Asia and Sub-Saharan Africa. The Global
 289 Disease Burden (GBD) studies suggested that, as of 2017, approximately 82% of all
 290 tetanus cases in the world were comprised of patients from these two regions, along
 291 with 77% of the total 38,000 tetanus deaths (4). Hence, it was pertinent to study the
 292 factors associated with mortality among patients who are already infected. This study
 293 is one of the few attempts in Bangladesh to explore the factors associated with in-
 294 hospital mortality of adult tetanus patients.

295 We found that nearly 34.4% of patients died in the hospital. This is higher than two
 296 previous studies from Bangladesh, where authors reported 22.5%(14) and 28.6%(5)
 297 deaths. However, the observed death rates show regional variations. For instance,

298 Tanon et al. reported a death rate of 30% in the Ivory Coast (15), and Marulappa et al.
299 found it to be 42.2% in India(16). The case-fatality rates appear to be considerably
300 lower where patients were provided ventilatory support. This can be seen in China (17)
301 and Nepal (18), where only 5.9% and 7.5% of deaths were reported, respectively.
302 However, despite giving mechanical ventilation, the death rate was 43.1% in
303 Tanzania(19), a lower-middle-income country, which raises the importance of overall
304 management facilities as well as other factors associated with deaths among tetanus
305 patients.

306 We noted that patients who died had a significantly higher mean age than those who
307 were alive, and patients with age ≥ 40 years had an increased chance of death in the
308 hospital. This finding is supported by previous observations in Bangladesh(5),
309 Tanzania(19), and India(16). Similar to ours, Chalya et al. (19) noted that patients aged
310 ≥ 40 years were significantly more likely to die when adjusted for other factors, such as
311 incubation period, onset time, presence of complications, prior immunization, and
312 tetanus severity.

313 The male population constituted the maximum number of participants in our study as
314 well as other studies reporting on tetanus cases(7,14–19). This probably reflects the
315 outcome of immunization strategies for women of childbearing age in all countries. The
316 WHO recommends three booster dosages of vaccine at ages: 12 – 23 months, 4 – 7
317 years, and 9 – 15 years for achieving life-long immunity for all (13). Although many
318 countries have programs for childhood immunization, expanding those to include

319 booster dosages remains challenging. Hence, the vulnerable male population should be
320 identified and vaccinated to protect them from tetanus ~~as a starter~~.

321 One important finding of our study is that more than half of the patients were farmers
322 and lived in rural areas. Similarly, many previous studies(16,19–22) observed a high
323 proportion of farmers among tetanus patients. As *C. tetani* spores remain in the
324 environment, people working in the fields, often with sharp cutting instruments, have a
325 higher chance of being exposed to the bacteria due to accidental punctures or lacerated
326 wounds. Farmers or agriculturists in low- and middle-income countries often work
327 barefooted without adequate personal protective measures in the fields(23). Therefore,
328 they could be treated as a high-risk group to prioritize primary and booster
329 immunization wherever appropriate.

330 We found that only 6.6% of patients could remember taking tetanus vaccine in the past
331 and only one-quarter of patients took postexposure prophylaxis. Similar observations
332 were reported by Khakheli et al. (22) and Tosun et al. (6). Patients tend to forget the
333 previous history of vaccination, and their attendants are even less likely to know about
334 their vaccination history, which explains the reports. However, a low frequency of post-
335 exposure prophylaxis indicates a lack of knowledge, awareness, and practice regarding
336 tetanus vaccination after injury, particularly minor injuries, among the general
337 population. Health authorities should work to address this issue where tetanus is not
338 uncommon.

339 Although an onset time (duration between onset of symptoms to full-blown
340 presentation) of 48 hours (2 days) and incubation of period of 7 days is used as a cutoff

341 point of determining the increased risk of fatality in the majority of studies exploring
342 prognostic factors of tetanus(2), we selected a higher cutoff point for both because the
343 median onset time and incubation period were high among our study participants. Our
344 analysis revealed that an onset time of ≤ 4 days and an incubation period of ≤ 12 days
345 significantly increased the chance of fatality of tetanus patients in the hospital.
346 However, after adjustment for age and the presence of complications, only onset time
347 (≤ 4 days) remained a significant determinant of in-hospital mortality. Previously,
348 Amare et al. (11) reported a univariate association of < 3 days onset time with mortality,
349 which became statistically nonsignificant after multivariate logistic adjustments.
350 Similarly, Krishnan et al. (12) and Chalya et al. (19) didn't find any association of onset
351 time (≤ 48 hours) with the death of tetanus patients. The incubation period of < 7 days
352 was found to be associated with a significantly increased risk of mortality in ~~several~~
353 previous reports(19,22). In contrast, some other reports did not find such an
354 association(7,11). However, very few studies have considered a higher incubation
355 period cutoff point for analysis, making it difficult to comment on the findings.
356 Additionally, differences in sample size and consideration of other factors during
357 multivariate adjustment as well as the type of analysis used, often influence the
358 outcome. Hence, the findings should be read in the context of a particular study.

359 The clinical presentation of tetanus shows variability in previous studies. The most
360 common symptoms among our patients included lockjaw (trismus), dysphagia, and
361 spasticity like previous observations in Bangladesh(5,14). We did not find any
362 noticeable differences in clinical features between alive and dead tetanus patients.
363 Neither did we find any remarkable differences in routine investigations of dead and

364 alive patients. Serum sodium levels were slightly but statistically significantly higher
365 in deceased patients than that of recovered ones. However, both groups had their values
366 within the normal limit. Therefore, the difference discovered could be a random finding
367 that needs to be evaluated through further large sample studies.

368 Unlike Chalya et al. (19), we did not find an increased risk of mortality in patients with
369 severe tetanus. But our finding is concordant with that of Amare et al. (11). However,
370 it might depend on the scales used for severity grading among patients. The Ablett
371 classification scheme used in our study is dependent on the presence of spasms and
372 autonomic disturbance, which evolve throughout the course of the disease (2). Hence it
373 is considered to be less suitable for prognostic stratification. Nevertheless, similar to
374 other studies(22), we noted that nearly 50% of patients presented with severe and very
375 severe disease.

376 In the present study, only 8.2% of participants had one or more comorbidities from
377 diabetes, hypertension, COPD, and ischemic heart disease. However, it was not
378 associated with a higher risk of mortality. Rather, the development of complication(s)
379 was associated with a significantly higher risk of death in the hospital, which is
380 concordant with findings from Marulappa et al. (16), Tanon et al. (15), Krishnan et al.
381 (12), and Bankole et al. (20). Hypoxemia and aspiration pneumonia were frequent
382 complications that we encountered in our patients. Hypoxemia is the consequence of
383 laryngeal spasms, respiratory distress, and respiratory failure that might occur in tetanus
384 patients(12). Unlike Amare et al. (11), who reported the occurrence of dysautonomia in
385 91.7% of deceased tetanus patients, we found the problem in only 9.5% of patients who

386 died. This could be explained by the lack of cardiac monitoring facilities and intensive
387 care units in our centers, the presence of which would have allowed close monitoring
388 and precise detection of autonomic imbalance in these patients. Moreover, life-saving
389 ventilatory supports for patients were not possible either because of the lack of
390 facilities.

391 **Limitations**

392 Our study had several limitations. The sample size was small.. The impact of ventilatory
393 support on mortality could not be evaluated due to a lack of facilities. Further follow-
394 up of patients after discharge from the hospital was also not possible. However, this
395 was one of the few attempts to assess the clinical-epidemiological profile and factors
396 associated with in-hospital mortality among tetanus patients in Bangladesh. Our
397 findings would undoubtedly spark interest in further studies and inform policymakers
398 regarding the limitations in the management of tetanus that need to be addressed.

399 **Recommendations**

400 Considering the findings of this study, we have the following recommendations-

- 401 1. Adult tetanus patients with a higher age should be given special care during
402 management.
- 403 2. A shorter onset time of tetanus must warrant careful assessment of disease
404 severity for meticulous treatment.
- 405 3. A booster vaccination program should be started prioritizing vulnerable male
406 population to prevent tetanus incidence in the country.

407 4. Further large-scale countrywide studies on tetanus patients should be carried out
408 to explore management strategies and reduce case-fatality among tetanus
409 patients.

410 **Conclusion**

411 Although expanded programs on immunization and maternal and neonatal tetanus
412 elimination programs have been successful in the considerable reduction of tetanus in
413 neonates, children, women of childbearing age, and men at their early adulthood, older
414 adult men are still vulnerable to tetanus in Bangladesh. As most of the cases come from
415 rural areas where farming and manual work are the principal modes of earning, they
416 could be considered a priority group for a booster vaccination program. On the other
417 hand, tetanus patients with higher age and shorter onset time needs special care during
418 management as they have a higher risk of death.

419

420 **Authors Declaration**

421 **Declaration of Competing Interest:** The authors declare that there are no conflicts of
422 interest.

423 **Authors Contribution:**

424 The conception of the study was generated by MASK. A detailed outline and design of
425 the study was prepared by MASK, MJH, SZ, SMS, AB, MDHH MHN and NSK. Data
426 collection, data acquisition and associated works were performed by MASK, SK, MUR,
427 and SKS. Data analysis was carried out by MASK. The first draft of the manuscript was
428 prepared by MASK. MASK, MJH, MUR, SKS, SK, SZ, SMS, AB, MDHH, MHN,
429 NSK, reviewed the draft and approved the final version.

430

431 **Data available:** Available upon reasonable request from the corresponding authors.

432 **Funding:** No funding was received for this study.

433 **Acknowledgement:** Authors acknowledge the contribution of the patients and their
434 guardians for their kind consent to participate in the study.

435

436

Reference:

1. Bennett JE, Dolin R, Blaser MJ. Infectious Disease Essentials. Philadelphia: Elsevier; 2017.
2. Yen LM, Thwaites CL. Tetanus. *Lancet*. 2019;393(10181):1657–68.
3. Woldeamanuel YW, Andemeskel AT, Kyei K, Woldeamanuel MW, Woldeamanuel W. Case fatality of adult tetanus in Africa: Systematic review and meta-analysis. *J Neurol Sci*. 2016;368:292–9.
4. Yen L, Thwaites C, Behrens H, Ochmann S, Danoaite B, Roser M. Tetanus [Internet]. OurWorldInData.org. 2019. p. 1657–68. Available from: <https://ourworldindata.org/tetanus>
5. Hasnain MG, Maruf S, Nath P, Anuwarul A, Ahmed MNU, Chowdhury IH, et al. Managing severe tetanus without ventilation support in a resource-limited setting in Bangladesh. *Am J Trop Med Hyg*. 2018;99(5):1234–8.
6. Tosun S, Batirel A, Oluk AI, Aksoy F, Puca E, Bénézit F, et al. Tetanus in adults: results of the multicenter ID-IRI study. *Eur J Clin Microbiol Infect Dis*. 2017;36(8):1455–62.
7. Saltoglu N, Tasova Y, Midikli D, Burgut R, Dünder IH. Prognostic factors affecting deaths from adult tetanus. *Clin Microbiol Infect*. 2004;10(3):229–33.
8. Erdem H, Inan A, Altindis S, Carevic B, Askarian M, Cottle L, et al. Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran - A prospective multicenter point prevalence

- study. *J Infect.* 2014;68(2):131–40.
9. Lisboa T, Ho Y-L, Henriques Filho GT, Brauner JS, Valiatti JLDS, Verdeal JC, et al. Guidelines for the management of accidental tetanus in adult patients. *Rev Bras Ter intensiva.* 2011;23(4):394–409.
 10. Ajose FOA, Odusanya OO. Survival from adult tetanus in Lagos, Nigeria. *Trop Doct.* 2009;39(1):39–40.
 11. Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: Clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. *J Neurol Sci.* 2012;317(1–2):62–5.
 12. Khrisnan L, Anam, Panigoro R. Factors Affecting Mortality in Adult Tetanus Patients. *Althea Med J.* 2015;2(2):157–62.
 13. World Health Organization. Protecting all against tetanus. Vol. 92. 2017. 1–6 p.
 14. Feroz A, Rahman M. A Ten-year Retrospective Study of Tetanus at a Teaching Hospital in Bangladesh. *J Bangladesh Coll Physicians Surg.* 2007;25(2).
 15. Tanon AK, Doumbia A, Coffie PA. Current Prognostic Factors of Tetanus in Abidjan: 2005-2014. *J Microbiol Infect Dis.* 2017;7(June):125–31.
 16. Marulappa VG, Manjunath R, Mahesh N, Maligegowda L. A ten year retrospective study on adult Tetanus at the epidemic disease (ED) hospital, Mysore in Southern India: A review of 512 cases. *J Clin Diagnostic Res.* 2012;6(8):1377–80.

17. Fan Z, Zhao Y, Wang S, Zhang F, Zhuang C. Clinical features and outcomes of tetanus: A retrospective study. *Infect Drug Resist.* 2019;12:1289–93.
18. Shah B, Subedi M, Bartaula B, Ghimire A. Retrospective chart- review of Tetanus cases admitted in a tertiary care hospital. *J Adv Intern Med.* 2020;9(2):69–72.
19. Chalya PL, Mabula JB, Dass RM, Mbelenge N, Mshana SE, Gilyoma JM. Ten-year experiences with Tetanus at a Tertiary hospital in Northwestern Tanzania: A retrospective review of 102 cases. *World J Emerg Surg.* 2011;6(1):2–9.
20. Bankole IA, Danesi MA, Ojo OO, Okubadejo NU, Ojini FI. Characteristics and outcome of tetanus in adolescent and adult patients admitted to the Lagos University Teaching Hospital between 2000 and 2009. *J Neurol Sci.* 2012;323(1–2):201–4.
21. Ramachandra L, Shobha K, Kannan PA. A Retrospective Clinical Study of Factors Affecting Tetanus. *internet J Microbiol.* 2008;7(1):1–6.
22. Khakheli MS, Khuhro BA, Jamali AH. Tetanus: Still a killer in adults. *Anaesthesia, Pain Intensive Care.* 2013;17(2):149–53.
23. Öncü SS, Önde M, Öncü SS, Ergin F, Öztürk B. Tetanus seroepidemiology and factors influencing immunity status among farmers of advanced age. *Health Policy (New York).* 2011;100(2–3):305–9.



Recovered Died

